TABLE 1.
Clinical characteristics of 34 non‐small‐cell lung cancer patients
| Characteristic | Total (n) | Proportion (%) | mPFS (m) | χ 2 value | p |
|---|---|---|---|---|---|
| Sex | |||||
| Male | 14 | 41.2% | 7.0 | 1.224 | 0.269 |
| Female | 20 | 58.8% | 6.0 | ||
| Age | |||||
| ≥65 | 21 | 61.8% | 6.0 | 0.885 | 0.347 |
| <65 | 13 | 38.2% | 7.0 | ||
| Smoking history | |||||
| Yes | 4 | 11.8% | 7.0 | 0.509 | 0.476 |
| No | 30 | 88.2% | 6.0 | ||
| ECOG PS | |||||
| 0–1 | 30 | 88.2% | 7.0 | 14.342 | 0.000* |
| 2 | 4 | 11.8% | 2.0 | ||
| EGFR genotype | |||||
| exon 19 del | 16 | 47.1% | 7.0 | 0.929 | 0.335 |
| exon 21 L858R | 18 | 52.9% | 4.0 | ||
| Family history | |||||
| Yes | 8 | 23.5% | 6.0 | 0.000 | 0.995 |
| No | 26 | 76.5% | 6.0 | ||
| Primary disease | |||||
| Yes | 21 | 61.8% | 6.0 | 0.062 | 0.804 |
| No | 13 | 38.2% | 6.0 | ||
| Prior chemotherapy | |||||
| Yes | 24 | 70.6% | 6.0 | 0.542 | 0.462 |
| No | 10 | 29.4% | 4.0 | ||
| Prior bevacizumab | |||||
| Yes | 8 | 23.5% | 6.0 | 0.011 | 0.917 |
| No | 26 | 76.5% | 6.0 | ||
| Prior radiotherapy | |||||
| Yes | 8 | 23.5% | 12.0 | 4.698 | 0.030* |
| No | 26 | 76.5% | 5.0 | ||
| Prior operation | |||||
| Yes | 12 | 35.3% | 4.0 | 0.205 | 0.650 |
| No | 22 | 64.5% | 6.0 | ||
| Brain metastases | |||||
| Yes | 16 | 47.1% | 4.0 | 4.380 | 0.036* |
| No | 18 | 52.9% | 7.0 | ||
| Bone metastases | |||||
| Yes | 8 | 23.5% | 4.0 | 5.195 | 0.023* |
| No | 26 | 76.5% | 7.0 | ||
| Liver metastases | |||||
| Yes | 3 | 8.8% | 2.0 | 2.626 | 0.105 |
| No | 31 | 91.2% | 6.0 | ||
| Pleural metastasis | |||||
| Yes | 8 | 23.5% | 4.0 | 0.865 | 0.352 |
| No | 26 | 76.5% | 6.0 | ||
| Malignant pleural effusion | |||||
| Yes | 6 | 17.6% | 4.0 | 3.613 | 0.057 |
| No | 28 | 82.4% | 7.0 |
Abbreviations: ECOG PS, eastern cooperative oncology group performance status; EGFR, epidermal growth factor receptor; mPFS, median progression‐free survival.
*
p < 0.05.